Test Price
2,800 AED✅ Home Collection Available
NAGLU Gene Sequencing for Mucopolysaccharidosis Type IIIB (Sanfilippo B) in UAE | 2800 AED | DHA-Regulated
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (8 AM – 11 PM daily).
- Clinical Guidance: Telephonic Post-Test Clinical Correlation with a DHA-Licensed Genetic Counsellor.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The NAGLU gene test identifies pathogenic variants responsible for Sanfilippo syndrome B (MPS IIIB), a lysosomal storage disorder causing severe neurodegeneration. In the UAE, early genetic diagnosis enables proactive multidisciplinary management and family planning. This Next-Generation Sequencing (NGS) analysis covers all coding exons and flanking intronic regions with Sanger confirmation of clinically significant variants.
| Feature | Our Test (NAGLU NGS) | Standard Single-Gene Sanger |
|---|---|---|
| Precision | >99.9% analytical sensitivity; complete exon & splice site coverage | Limited to known hotspots; may miss deep intronic variants |
| Methodology | Illumina Next-Generation Sequencing (NGS) with Sanger confirmation | Sanger sequencing of selected exons |
| Turnaround Time | 3–4 Weeks (including variant interpretation) | 4–6 Weeks, often without bioinformatics annotation |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh (Consultant Medical Genetics, DHA Registration ID: 9294403) advises: “A positive NAGLU variant requires correlation with clinical symptoms and biochemical assays; this test is not a standalone diagnostic. Please maintain all existing treatments and consult your metabolic specialist before any changes. Early intervention and genetic counselling are vital for families navigating MPS IIIB.”
Critical Advisory
Medication Warning
Do not discontinue prescribed enzyme replacement therapies, nutritional support, or symptomatic medications without consulting your DHA-licensed physician. Abrupt cessation may accelerate neurological deterioration.
Exclusion Criteria & Red Flags
- Patient must be hemodynamically stable for blood draw; active bleeding disorders require clinical clearance.
- If the individual is a minor (<18 years), mandatory consent from a legal guardian is required per UAE law.
- Emergency symptoms prompting immediate care: acute seizures, severe aspiration pneumonia, or loss of consciousness. Do not delay medical attention for test scheduling.
- Specimen must not be contaminated; a repeat sample may be requested.
Patient FAQ & Clinical Guidance
1. What exactly does the NAGLU NGS test detect and how reliable is it for UAE patients?
The NAGLU NGS test sequences all coding exons and flanking intronic regions of the NAGLU gene, identifying pathogenic variants linked to Mucopolysaccharidosis Type IIIB (Sanfilippo B) with 99.9% diagnostic sensitivity. This test is DHA-regulated and ISO 9001:2015 certified.
2. For minors, what legal consents are needed per UAE law?
Under UAE Federal Decree-Law No. 4 of 2016 on Medical Liability and the Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL), genetic testing of minors mandates notarized consent from both parents or legal guardian, alongside pre-genetic counselling.
3. How does the home collection service ensure sample integrity and confidentiality?
Our ISO 9001:2015 certified cold-chain home collection uses temperature-controlled transport and tamper-evident kits, maintaining DNA stability from vein to lab, with data privacy enforced under UAE PDPL (Federal Decree-Law No. 45 of 2021) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
UAE Regulatory & Data Privacy Adherence
This genetic test is fully compliant with UAE Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. DNA Labs UAE is DHA-licensed (Facility License No. 1143) and ISO 9001:2015 certified.
Clinical & Logistical Metadata
| Test Name | NAGLU Gene Sequencing for Mucopolysaccharidosis Type IIIB (Sanfilippo B) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (EDTA tube, 3-5 mL) |
| Methodology Used | Next-Generation Sequencing (NGS) with Sanger Confirmation |
| ICD-10-CM Code | E76.22 |
| LOINC Code | 94147-2 |
| DHA Facility License & Laboratory Address | Facility License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians